This trial is active, not recruiting.

Conditions atherosclerotic renal artery stenosis, ischemic nephropathy, renovascular hypertension
Treatment arterial infusion of autologous mesenchymal stem cells
Phase phase 1
Sponsor Mayo Clinic
Start date April 2013
End date March 2014
Trial size 6 participants
Trial identifier NCT01840540, 12-009298


To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
arterial infusion of autologous mesenchymal stem cells MSC

Primary Outcomes

Renal blood flow and function in the treated kidneys.
time frame: 2 years

Secondary Outcomes

Level of kidney function.
time frame: 2 years

Eligibility Criteria

Male or female participants from 40 years up to 80 years old.

4.1 Inclusion Criteria 1. Are between ages 40 and 80 years old. 2. Advanced vascular occlusive disease (atherosclerosis) affecting one or both kidneys: defined as a) loss of parenchymal volume and renal blood flow (measured by MDCT as previously described (17) and/or duplex ultrasound velocity above 300 cm/sec to the affected kidney to be infused with MSC's. 3. Have serum creatinine below 2.5 mg/dL 4. Have no-contraindications to angiography: severe contrast allergy 5. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia 6. Ability to comply with protocol 7. Competent and able to provide written informed consent 4.2 Exclusion Criteria 1. Advanced CKD: Stage 5 (two kidney eGFR < 15 ml/min/1.73 m2) contralateral renal artery occlusion/stenosis above 75% or ESRD requiring dialysis 2. Clinically significant abnormalities on laboratory examination, including Bilirubin (> 2 x normal), platelets (<100 thousand), potassium (>5.5 mEq/L), and sodium (<130 mEq/L), ALT or AST more than 2 x normal, Prothrombin time (INR>1.4), Hemoglobin <10.0 g/dL. 3. Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure) that would, in the opinion of the investigators, compromise the safety of the patient. 4. Specific exclusions: 1. Clinical history of deep vein thrombosis within three months of MSC administration 2. Uncontrolled hypertension (Systolic BP >180 mmHg despite therapy) 3. Active infection 4. Reduced ejection fraction (below 30%) 5. Evidence of hepatitis B,C, or HIV 6. Diabetes treated with insulin and/or glucose lowering agents 7. Anemia (Hgb<10 g/dL) 8. Regular use of potentially renotoxic drugs, e.g. non-steroidal anti-inflammatory agents (NSAID's): (>2 x weekly) 5. History of cancer including melanoma (with the exception of localized skin cancers) 6. Investigational drug exposure within thirty (30) days of baseline 7. Beck's depression score above 16 8. Pregnant or breast feeding. 9. History of clinically significant auto-immunity or any previous example of fat-directed autoimmunity

Additional Information

Official title Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis
Principal investigator Stephen Textor, MD
Description Individuals with unilateral arterial occlusive disease will be treated to injured kidney with autologous cells.
Trial information was received from ClinicalTrials.gov and was last updated in October 2015.
Information provided to ClinicalTrials.gov by Mayo Clinic.